About Atrial Fibrillation
Atrial fibrillation (AF) is a major cause of hospitalization and mortality and affects about 2.5 million people in the United States, as well as 4.5 million people in the European Union and is emerging as a growing public health concern due to an aging population. In atrial fibrillation, some blood inside the atria may stagnate, and clots may form. If a piece of the clot breaks off and subsequently blocks an artery in the brain, a stroke results. According to the joint ACC/AHA/ESC guidelines for the management of atrial fibrillation, patients with atrial fibrillation have a two- to seven-fold increased risk of stroke and also have an increased risk of death and cardiovascular complications, including myocardial infarction.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current treatments for cardiovascular and inflammatory diseases and cancer.
Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa
inhibitor and PRT060128, an ADP receptor antagonist, target the global
multi- billion dollar antithrombotic market. Both product candidates have
best-in- class features versus current and novel agents in development,
addressing the hospital, specialty, and chronic care markets. The Company's
earlier-stage programs are leveraging its chemistry and kinase expertise to
develop specific Syk and JAK inhibitors to treat cancer and inflammatory
diseases with broader activity. The company also has a novel anticoagulant
antidote program with the potential to help manage the more than 20 million
patients expected to be treated with anticoagulants worldwide in the next
decade. For additional information, visit
|SOURCE Portola Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved